Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 253

Similar articles for PubMed (Select 23053286)

1.

Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.

Ke HL, Ke RH, Li B, Wang XH, Wang YN, Wang XQ.

Acta Neurochir (Wien). 2013 Jan;155(1):165-71. doi: 10.1007/s00701-012-1512-0. Epub 2012 Oct 5.

PMID:
23053286
2.

Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.

Ke HL, Ke RH, Li ST, Li B, Lu HT, Wang XQ.

J Neurooncol. 2013 Jun;113(2):327-32. doi: 10.1007/s11060-013-1121-7. Epub 2013 Mar 25.

PMID:
23525949
3.

Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.

Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY.

J Neurooncol. 2010 Nov;100(2):217-23. doi: 10.1007/s11060-010-0164-2. Epub 2010 Apr 29.

PMID:
20428925
4.

A study of UbcH10 expression and its association with recurrence of meningiomas.

Jiang L, Wang T, Bao Y, Qian J, Wu XJ, Hu GH, Lu YC.

J Surg Oncol. 2012 Sep 1;106(3):327-31. doi: 10.1002/jso.22141. Epub 2011 Nov 17.

PMID:
22095464
5.

Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.

Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A.

APMIS. 2009 Sep;117(9):651-9. doi: 10.1111/j.1600-0463.2009.02516.x.

PMID:
19703125
6.

Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.

Caltabiano R, Barbagallo GM, Castaing M, Cassenti A, Senetta R, Cassoni P, Albanese V, Lanzafame S.

J Neurosurg Sci. 2013 Jun;57(2):139-51. Epub 2013 Mar 13.

PMID:
23486338
7.

DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.

Menghi F, Orzan FN, Eoli M, Farinotti M, Maderna E, Pisati F, Bianchessi D, Valletta L, Lodrini S, Galli G, Anghileri E, Pellegatta S, Pollo B, Finocchiaro G.

Oncologist. 2011;16(10):1440-50. doi: 10.1634/theoncologist.2010-0249. Epub 2011 Sep 23.

8.

Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.

Ruiz J, Martínez A, Hernández S, Zimman H, Ferrer M, Fernández C, Sáez M, López-Asenjo JA, Sanz-Ortega J.

Histol Histopathol. 2010 Mar;25(3):341-9.

PMID:
20054806
9.

Clinical features and treatment of World Health Organization grade II and III meningiomas in childhood: report of 23 cases.

Wang XQ, Jiang CC, Zhao L, Gong Y, Hu J, Chen H.

J Neurosurg Pediatr. 2012 Nov;10(5):423-33. doi: 10.3171/2012.7.PEDS12179. Epub 2012 Aug 31. Erratum in: J Neurosurg Pediatr. 2012 Nov;10(5):459.

PMID:
22938082
10.

Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas.

Lee SH, Lee YS, Hong YG, Kang CS.

APMIS. 2014 Jan;122(1):16-24. doi: 10.1111/apm.12079. Epub 2013 Jun 12.

PMID:
23756256
11.

Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches.

Preusser M, Hassler M, Birner P, Rudas M, Acker T, Plate KH, Widhalm G, Knosp E, Breitschopf H, Berger J, Marosi C.

Clin Neuropathol. 2012 Sep-Oct;31(5):352-60. doi: 10.5414/NP300488.

PMID:
22541785
12.

EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas.

Tsai WC, Chen Y, Huang LC, Lee HS, Ma HI, Huang SM, Sytwu HK, Hueng DY.

J Neurooncol. 2013 Sep;114(3):281-90. doi: 10.1007/s11060-013-1184-5. Epub 2013 Jul 2.

13.

Association between laminin-8 and glial tumor grade, recurrence, and patient survival.

Ljubimova JY, Fugita M, Khazenzon NM, Das A, Pikul BB, Newman D, Sekiguchi K, Sorokin LM, Sasaki T, Black KL.

Cancer. 2004 Aug 1;101(3):604-12.

14.

Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.

Trinkaus M, Vranic A, Dolenc VV, Lah TT.

Int J Biol Markers. 2005 Jan-Mar;20(1):50-9.

PMID:
15832773
15.

Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.

Skiriute D, Tamasauskas S, Asmoniene V, Saferis V, Skauminas K, Deltuva V, Tamasauskas A.

J Neurooncol. 2011 Mar;102(1):89-94. doi: 10.1007/s11060-010-0291-9. Epub 2010 Jul 4.

PMID:
20607352
16.

[Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].

Korshunov AG, Shishkina LV, Golanov AV.

Arkh Patol. 2002 Jan-Feb;64(1):29-33. Russian.

PMID:
11889696
17.

The expression of fatty acid metabolism-associated proteins is correlated with the prognosis of meningiomas.

Jiang J, Lin C, Liu N, Zhang Z, Sun Y, Fang X, Qi J.

APMIS. 2013 Oct;121(10):997-1003. doi: 10.1111/apm.12135. Epub 2013 Jul 24.

PMID:
23879478
18.

Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.

Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Fèvre-Montange M.

Clin Neuropathol. 2008 Sep-Oct;27(5):334-45.

19.

WHO grade II and III meningiomas: a study of prognostic factors.

Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, Fèvre-Montange M, Guyotat J.

J Neurooncol. 2009 Dec;95(3):367-75. doi: 10.1007/s11060-009-9934-0. Epub 2009 Jun 27.

PMID:
19562258
20.

Molecular biological determinations of meningioma progression and recurrence.

Linsler S, Kraemer D, Driess C, Oertel J, Kammers K, Rahnenführer J, Ketter R, Urbschat S.

PLoS One. 2014 Apr 10;9(4):e94987. doi: 10.1371/journal.pone.0094987. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk